Drug Trial Radar · NCT00281515
Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Jun 29, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jan 2006
Primary completion
Dec 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- AGO Study GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 25, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin in primary treatment of patients with epithelial ovarian cancer.
Conditions
- Epithelial Ovarian Cancer
Interventions
LonafarnibDrug
100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: every 3 months until PD
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Klinik für Frauenheilkunde
Berlin, Germany
Klinikum Bremen Mitte, Frauenklinik
Bremen, Germany
Carl-Gustav-Carus der TU Dresden, Universitäts-Frauenklinik
Dresden, Germany
Ev. Krankenhaus, Frauenklinik
Düsseldorf, Germany
Klinik für Frauenheilkunde der Univ. Erlangen
Erlangen, Germany
Universitätsfrauenklinik
Essen, Germany
Klinikum der Johann Wolfgang Goethe Universität, Klinik für Frauenheilkunde u. Geburtshilfe
Frankfurt, Germany
Universitätsklinikum Freiburg, Frauenklinik
Freiburg im Breisgau, Germany
Kreiskrankenhaus, Frauenklinik
Gifhorn, Germany
Klinik u. Poliklinik für Gynäkologie und Geburtshilfe
Greifswald, Germany
Medizinische Hochschule
Hanover, Germany
St. Vincentius-Krankenhäuser
Karlsruhe, Germany
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Gynäkologie und Geburtshilfe
Kiel, Germany
Klinik der Otto-von-Guericke Universität, Frauenklinik
Magdeburg, Germany
Johannes-Gutenberg-Universität, Universitäts-Frauenklinik
Mainz, Germany
Klinikum der Philipps-Universität Marburg, Klinik für Gynäkologie, Gynäkologische Endokrinologie
Marburg, Germany
Klinikum Großhadern, Frauenklinik
München, Germany
Klinikum rechts der Isar der TU München
München, Germany
Elblandkliniken, Frauenklinik
Radebeul, Germany
Klinikum Südstadt
Rostock, Germany
Universitäts-Frauenklinik
Tübingen, Germany
Universitätsfrauenklinik
Ulm, Germany
Dr. Horst Schmidt Klinik, Gynäkologie u. Gynäkologische Onkologie
Wiesbaden, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.